ICM
TRIB

Invenomic Capital Management’s Trinity Biotech TRIB Stock Holding History

Invenomic Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-898
Closed -$293K – 177
2020
Q2 		$293K Sell
898
-1,775
-66% -$406K 0.22% 115
2020
Q1 		$441K Sell
2,673
-734
-22% -$115K 0.36% 78
2019
Q4 		$526K Buy
+3,407
New +$486K 0.21% 94

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Invenomic Capital Management's TRIB Position: Q3 2020 in Review

Invenomic Capital Management sold out of Trinity Biotech (TRIB) in Q3 2020, closing a stake of 898 shares — an estimated $293K sold.

Invenomic Capital Management first reported a position in TRIB in Q4 2019 and held it in 3 quarters. The position peaked at $526K in Q4 2019. 23 funds tracked by Wall St. Rank hold TRIB as of Q3 2020.

  • Invenomic Capital Management reported no remaining Trinity Biotech position as of Q3 2020 after selling out during the quarter.
  • Invenomic Capital Management sold 898 Trinity Biotech shares in Q3 2020, an estimated $293K.
  • Invenomic Capital Management first reported a position in Trinity Biotech in Q4 2019 and held it in 3 quarters.
  • Invenomic Capital Management's Trinity Biotech position peaked at $526K in Q4 2019.
  • 23 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2020.

Based on Invenomic Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.